Login to Your Account



Indivior stock rises on phase III data in opioid dependence

By Cormac Sheridan
Staff Writer

Wednesday, August 17, 2016

DUBLIN – Shares in Indivior plc rose more than 21 percent to an all-time high during early trading Wednesday on news that RBP-6000, a once-per-month depot injection of buprenorphine, hit the primary endpoint of a phase III trial in patients with opioid use disorder.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription